Finance entity
Collegium Pharmaceutical, Inc. is most often covered alongside Belbuca, which appears in 1 of these 2 stories. The 17-day window averages about 0.8 stories each week. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Collegium Pharmaceutical, Inc. is most often covered alongside Belbuca, which appears in 1 of these 2 stories. The 17-day window averages about 0.8 stories each week. At 5, the average consequence score sits below the same-window beat average of 6.3. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Finance stories that mention Collegium Pharmaceutical, Inc., published between February 27, 2026 and March 15, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1252 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Eventide Rebalancing
Eventide Asset Management reports a reduced but significant stake of $83.65 million in Collegium.
Institutional Reduction
Integrated Quantitative Investments LLC reduces its stock position in COLL.
Truist Analysis
Truist Securities highlights momentum for Jornay PM and a robust pain portfolio.
BDSI Acquisition
Collegium completes the acquisition of BioDelivery Sciences International, adding Belbuca to its portfolio.
Eventide Asset Management LLC has reduced its equity position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional shift comes as the specialty pharmaceutical firm navigates a shifting landscape for chronic pain management and expands into neurology.
CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.
Collegium Pharmaceutical, Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
